Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 5/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 16/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724075 | 0.92 | SCD (0.40) | LDHAPTGER1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL5724885 | 0.90 | PTGER1 (0.41) | LDHAPTGER1CYP1A2CYP2C19KDM4E | |
| SCHEMBL5724647 | 0.90 | PTGER1 (0.41) | LDHAPTGER1CYP1A2CYP2C19KDM4E | |
| SCHEMBL5723868 | 0.88 | NPC1 (0.41) | CYP1A2CYP2C19KDM4EALDH1A1POLB | |
| SCHEMBL5724210 | 0.88 | NPC1 (0.38) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL5724321 | 0.88 | TDP1 (0.42) | CYP1A2CYP2C19KDM4EALDH1A1POLB | |
| SCHEMBL6839029 | 0.87 | ACKR3 (0.35) | — | |
| SCHEMBL5724200 | 0.87 | MEN1 (0.39) | PTGER1KDM4EALDH1A1POLBL3MBTL1 | |
| SCHEMBL5724416 | 0.86 | HTR2C (0.36) | ALDH1A1L3MBTL1 | |
| SCHEMBL5724523 | 0.86 | RIPK1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | LDHA 1291/4885PTGER1 140/4885CYP1A2 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.